BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2810 related articles for article (PubMed ID: 19005398)

  • 21. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus.
    McAlister VC; Peltekian KM; Malatjalian DA; Colohan S; MacDonald S; Bitter-Suermann H; MacDonald AS
    Liver Transpl; 2001 Aug; 7(8):701-8. PubMed ID: 11510015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
    Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine A European Multicentric Study in kidney transplant patients.
    Morales JM; Andrés A; Dominguez-Gil B; Arriola M; Gutiérrez MJ; Hernández E; Ortuño T; Praga M
    Transplant Proc; 2005 Nov; 37(9):3738-42. PubMed ID: 16386523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of immediate switch from cyclosporine microemulsion to tacrolimus at first acute rejection in renal allograft recipients.
    Briggs D; Dudley C; Pattison J; Pfeffer P; Salmela K; Rowe P; Tydén G;
    Transplantation; 2003 Jun; 75(12):2058-63. PubMed ID: 12829912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Statins benefit outcomes of renal transplant recipients on a sirolimus-cyclosporine regimen.
    Lisik W; Schoenberg L; Lasky RE; Kahan BD
    Transplant Proc; 2007 Dec; 39(10):3086-92. PubMed ID: 18089328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New approaches to de novo immunosuppression and steroid elimination.
    Lebranchu Y
    Transplant Proc; 2009; 41(6 Suppl):S39-41. PubMed ID: 19651295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor.
    Durrbach A; Rostaing L; Tricot L; Ouali N; Wolf P; Pouteil-Noble C; Kessler M; Viron B; Thervet E
    Transplantation; 2008 Feb; 85(3):486-90. PubMed ID: 18301342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
    Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Al-Waheeb S; Hasaneen H; Awadain WH; Nawas KM; El-Sayed A; Said T; Nair MP; Nampoory MR
    Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
    Bolin P; Shihab FS; Mulloy L; Henning AK; Gao J; Bartucci M; Holman J; First MR;
    Transplantation; 2008 Jul; 86(1):88-95. PubMed ID: 18622283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different effect of cyclosporine and tacrolimus on renal expression of P-glycoprotein in human kidney transplantation.
    Yu X; Zhang B; Xing C; Sun B; Liu M; Zhang W; Gu M
    Transplant Proc; 2008 Dec; 40(10):3455-9. PubMed ID: 19100412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three-year health-related quality-of-life outcomes for sirolimus-treated kidney transplant patients after elimination of cyclosporine.
    Russ G; Jamieson N; Oberbauer R; Arias M; Murgia MG; Blancho G; Sato R; Stoeckl M; Revicki DA
    Transpl Int; 2007 Oct; 20(10):875-83. PubMed ID: 17854445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conversion to sirolimus allows preservation of renal function in kidney and kidney-pancreas allograft recipients.
    Laham G; Sleiman S; Soler Pujol G; Diaz C; Dávalos M; Vilches A
    Transplant Proc; 2010; 42(1):309-13. PubMed ID: 20172338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
    Lloberas N; Torras J; Alperovich G; Cruzado JM; Giménez-Bonafé P; Herrero-Fresneda I; Franquesa Ml; Rama I; Grinyó JM
    Nephrol Dial Transplant; 2008 Oct; 23(10):3111-9. PubMed ID: 18469305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine.
    Romagnoli J; Citterio F; Nanni G; Favi E; Tondolo V; Spagnoletti G; Salerno MP; Castagneto M
    Transplant Proc; 2006 May; 38(4):1034-6. PubMed ID: 16757255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
    Ross H; Pflugfelder P; Haddad H; Cantarovich M; White M; Ignaszewski A; Howlett J; Vaillancourt M; Dorent R; Burton JR;
    J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study.
    Ekberg H; Mamelok RD; Pearson TC; Vincenti F; Tedesco-Silva H; Daloze P
    Transplantation; 2009 May; 87(9):1360-6. PubMed ID: 19424036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
    Pascual J; del Castillo D; Cabello M; Pallardó L; Grinyó JM; Fernández AM; Brunet M
    Transplantation; 2010 Apr; 89(8):994-1000. PubMed ID: 20335831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 141.